Public Health England (PHE) National Mycobacterium Reference Laboratory, Clinical TB and HIV Group, Blizard Institute, Queen Mary University of London, London, UK.
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK.
Nat Genet. 2014 Mar;46(3):279-86. doi: 10.1038/ng.2878. Epub 2014 Jan 26.
The molecular mechanisms determining the transmissibility and prevalence of drug-resistant tuberculosis in a population were investigated through whole-genome sequencing of 1,000 prospectively obtained patient isolates from Russia. Two-thirds belonged to the Beijing lineage, which was dominated by two homogeneous clades. Multidrug-resistant (MDR) genotypes were found in 48% of isolates overall and in 87% of the major clades. The most common rpoB mutation was associated with fitness-compensatory mutations in rpoA or rpoC, and a new intragenic compensatory substitution was identified. The proportion of MDR cases with extensively drug-resistant (XDR) tuberculosis was 16% overall, with 65% of MDR isolates harboring eis mutations, selected by kanamycin therapy, which may drive the expansion of strains with enhanced virulence. The combination of drug resistance and compensatory mutations displayed by the major clades confers clinical resistance without compromising fitness and transmissibility, showing that, in addition to weaknesses in the tuberculosis control program, biological factors drive the persistence and spread of MDR and XDR tuberculosis in Russia and beyond.
通过对来自俄罗斯的 1000 例前瞻性患者分离株进行全基因组测序,研究了决定耐药结核病在人群中传播和流行的分子机制。三分之二的分离株属于北京家族,其中两个同源分支占主导地位。总体而言,48%的分离株存在耐多药(MDR)基因型,87%的主要分支存在该基因型。最常见的 rpoB 突变与 rpoA 或 rpoC 中的适应性补偿突变相关,并且鉴定出了一种新的基因内补偿性替代。耐多药病例中广泛耐药(XDR)结核病的比例为 16%,65%的耐多药分离株携带 eis 突变,这是由卡那霉素治疗选择的,可能会导致毒力增强的菌株的扩展。主要分支表现出的药物耐药性和补偿性突变赋予了临床耐药性而不影响适应性和传播性,表明除了结核病控制计划的薄弱环节外,生物因素还推动了 MDR 和 XDR 结核病在俄罗斯及其他地区的持续存在和传播。